Associated Papers
Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort.
Lu X et al.
Biomedicines, 2026
41595714 (PubMed )
Supplement: biomedicines-14-00180-s001.zip › biomedicines-4047568-supplementary.pdf
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
40705880 (PubMed )
Supplement: science.ads0239_data_s1_to_s6.zip › science.ads0239_data_s4.xlsx › Sheet1
Structural basis for transcription factor ZBTB7A recognition of DNA and effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia.
Ren R et al.
The Journal of Biological Chemistry, 2023
The clinical mutatome of core binding factor leukemia.
Opatz S et al.
Leukemia, 2020
31896782 (PubMed )
Supplement: 41375_2019_697_MOESM1_ESM.pdf
ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.
Redondo Monte E et al.
Oncogene, 2020
SNP-array lesions in core binding factor acute myeloid leukemia.
Duployez N et al.
Oncotarget, 2018
ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
Hartmann L et al.
Nature Communications, 2016
Select a paper to view details